Pazopanib Impurity 13

Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping
Yan Li 1, David Q Liu, Shawn Yang, Ravinder Sudini, Michael A McGuire, Dharmesh S Bhanushali, Alireza S Kord
J Pharm Biomed Anal. 2010 Aug 1;52(4):493-507.
 
Determination and characterization of process impurities in pazopanib hydrochloride drug substance
musty sharada, ravichandra babu
Int J Pharm Pharm Sci, Vol 8, Issue 4, 97-102
 
Characterization of forced degradation products of pazopanib hydrochloride by UHPLC‐Q‐TOF/MS and in silico toxicity prediction
Prinesh N. Patel  Pradipbhai D. Kalariya  Mahesh Sharma  Prabha Garg  M. V. N Kumar Talluri  S. Gananadhamu  R. Srinivas
Journal of mass spectrometry Volume50, Issue7 July 2015 Pages 918-928
 
Development and validation of a stability indicating RP-HPLC method for the determination of Pazopanib in bulk drug and its pharmaceutical dosage form
Kishore Kumar Reddy Y, J. Raveendra Reddy and N. Devanna
J. Chem. Pharm. Res., 2015, 7(9):127-132
 
Validated RP-HPLC Method Development of Pazopanib in Bulk and its Pharmaceutical Dosage Form
Kiran Kumar Buralla, and Varadarajan Parthasarathy
Pharmaceutical Methods,2020,11,1,21-24.

Pazopanib Impurity 13 is chemically 2,4-Dichloropyrimidine. Pazopanib Impurity 13 is supplied with detailed characterization data compliant with regulatory guideline. Pazopanib Impurity 13 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Pazopanib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.